The human NAD metabolome: Functions, metabolism and compartmentalization

Andrey Nikiforov, Veronika Kulikova & Mathias Ziegler

REVIEW ARTICLE

The human NAD metabolome: Functions, metabolism and compartmentalization

Andrey Nikiforov[1,2], Veronika Kulikova[1], and Mathias Ziegler[3]

[1]Institute of Nanobiotechnologies, St. Petersburg State Polytechnical University, St. Petersburg, Russia, [2]Institute of Cytology, Russian Academy of Sciences, St. Petersburg, Russia, and [3]Department of Molecular Biology, University of Bergen, Bergen, Norway

Abstract

The metabolism of NAD has emerged as a key regulator of cellular and organismal homeostasis. Being a major component of both bioenergetic and signaling pathways, the molecule is ideally suited to regulate metabolism and major cellular events. In humans, NAD is synthesized from vitamin B3 precursors, most prominently from nicotinamide, which is the degradation product of all NAD-dependent signaling reactions. The scope of NAD-mediated regulatory processes is wide including enzyme regulation, control of gene expression and health span, DNA repair, cell cycle regulation and calcium signaling. In these processes, nicotinamide is cleaved from NAD^+ and the remaining ADP-ribosyl moiety used to modify proteins (deacetylation by sirtuins or ADP-ribosylation) or to generate calcium-mobilizing agents such as cyclic ADP-ribose. This review will also emphasize the role of the intermediates in the NAD metabolome, their intra- and extra-cellular conversions and potential contributions to subcellular compartmentalization of NAD pools.

Introduction

NAD is an essential redox carrier, whereas its degradation is a key element of a wide range of signaling pathways (Belenky *et al*., 2007a; Berger *et al*., 2004; Houtkooper *et al*., 2010; Magni *et al*., 2008). The molecule is used for protein modifications (deacetylation, ADP-ribosylation) and as precursor of messenger molecules. It is becoming increasingly clear that NAD-mediated signaling processes are ubiquitously present throughout all the organisms and that they are involved not just in the metabolic adjustment to environmental changes, but rather participate in the control of fundamental cellular events. In addition, there are also cell- and tissue-specific processes which are subject to NAD-mediated regulation. For example, insulin secretion is regulated by four different mechanisms of NAD-dependent signaling (Antonelli

& Ferrannini, 2004; Haigis *et al*., 2006; Takasawa & Okamoto, 2002). Over the last years, NAD-dependent processes have emerged as highly promising targets for therapeutic applications to treat diseases such as cancer, diabetes, obesity and others. It is also noteworthy that supplementation of NAD precursors has a variety of beneficial effects, in particular, to improve cellular bioenergetics and metabolism.

The realization that, unlike redox reactions, signaling causes permanent NAD degradation prompted in-depth analyses of the biosynthetic pathways. They, too, constitute a complex array of conversions with emerging regulatory roles and relationships to the signaling processes, besides feeding energetic needs. There is no doubt that the studies of NAD-mediated signaling processes and the molecular understanding of NAD biosynthesis have moved far beyond the stage of being an ''emerging'' field. However, while the importance of NAD-dependent signaling pathways has been impressively demonstrated, even at the organismal level, some key issues have still remained elusive. To address these open questions, it appears important to understand the interconversions of intermediates of NAD biosynthesis and signaling, how these intermediates are provided to different subcellular compartments, and how they contribute to the maintenance of individual NAD pools. Rather surprisingly, it has also remained largely unclear how extracellular NAD and its derivatives can be utilized to serve as intracellular NAD precursors. This article is intended to provide an overview of the current knowledge regarding NAD biosynthesis and NAD-dependent signaling pathways,

Address for correspondence: Mathias Ziegler, Department of Molecular Biology, University of Bergen, Thormøhlensgate 55, 5008 Bergen, Norway. Tel: +47 555 84591. Fax: +47 555 89683. E-mail: mathias.ziegler@mbi.uib.no
Andrey Nikiforov, Institute of Nanobiotechnologies, St. Petersburg State Polytechnical University, Polytechnicheskaya 29, 195251, St. Petersburg, Russia. Tel: +7 812 5529809. Fax: +7 812 5528579. E-mail: andrey.nikiforov@gmail.com

topics that have been covered in much detail in several recent reviews (see below). Here, we have particularly focused on the intra- and extra-cellular conversions and the subcellular distribution of NAD and its precursors. As will be discussed, these aspects are important to understand the physiology of NAD metabolism and signaling and therefore need to be explored in more detail.

NAD biosynthesis in human cells

Maintenance of intracellular NAD pools is not only important to fuel redox metabolism, but also to support NAD-dependent signaling pathways (Figure 1). Since NAD-dependent signaling is accompanied by the degradation of NAD^+, cells need to permanently replenish these pools. Indeed, blocking NAD biosynthesis, for example, by inhibiting the transformation of precursors, leads to a marked decrease of the intracellular NAD content within a few hours (Pittelli *et al.*, 2010).

NAD is synthesized from extracellular precursors that are provided by the diet and need to enter cells (Figure 1). These precursors encompass the bases (nicotinamide [Nam] and nicotinic acid [NA]) and nucleosides (nicotinamide riboside [NR] and nicotinic acid riboside [NAR]) now collectively referred to as vitamin B3 (Bogan & Brenner, 2008; Magni *et al.*, 2008). Moreover, tryptophan degradation via the kynurenine pathway leads to the generation of quinolinic acid (QA), which is converted to NA mononucleotide (NAMN), an intermediate of NAD metabolism. The uptake of NAD precursors into cells is so far poorly understood. Transporters for tryptophan (SLC7A5 and SLC36A4) and NA (SLC5A8 and SLC22A13) have been identified (Bahn *et al.*, 2008; Gopal *et al.*, 2007; Kanai *et al.*, 1998; Pillai & Meredith, 2011), whereas the uptake of NR and NAR through equilibrative nucleoside transporters (ENTs) has been suggested based on pharmacological sensitivity (Nikiforov *et al.*, 2011) (Figure 1).

In general, when considering different pathways of NAD biosynthesis, the major aspect is the generation of the mononucleotide (NMN or NAMN), because formation of the dinucleotide is common to all known routes (Figure 1). Moreover, dinucleotide formation consists of the adenylation of the pyridine mononucleotide. The adenylyl group originates from ATP, a molecule that is abundantly available. It has now been established that formation of pyridine mononucleotides follows the same principal scheme as found for others such as purine and pyrimidine mononucleotides. That is, bases can be converted directly to the mononucleotides using phosphoribosyltransferases (PRTs). These enzymes catalyze the reaction between the base and phosphoribosylpyrophosphate (PRPP), resulting in the formation of the 5′-mononucleotide and the release of pyrophosphate (PPi; Figure 1).

Thus, the reaction using NA as base is catalyzed by NAPRT yielding NAMN. This pathway including the subsequent dinucleotide formation and amidation of the nicotinic acid moiety (Figure 1) is called the Preiss–Handler pathway in honor of its discoverers (Preiss & Handler, 1958a,b). NAMN is also the product of the reaction mediated by QAPRT. A specific aspect of this reaction is the simultaneous decarboxylation at the 2′ position of QA (pyridine-2,3-dicarboxylic acid). QAPRT activity could be important,

especially in the brain, to remove QA, which is highly neurotoxic (Guillemin, 2012). NAD biosynthesis from tryptophan via QA has been termed *de novo* pathway, because it includes the formation of the pyridine ring.

Nam is converted to NMN by NamPRT. This enzyme is also widely known as NAMPT, however, we will use NamPRT in this article, in keeping with the general denomination of phosphoribosyltransferases as PRTs. NamPRT has been intensely studied over the last years, because it appears to be crucial for human NAD metabolism, but also, because the enzyme may have roles not only within cells, but may also be secreted by some cell types such as adipocytes (Fukuhara *et al.*, 2005), refer the ''Extracellular NAD metabolites and their degradation'' section. The critical importance of NamPRT to maintain mammalian NAD homeostasis has been established by the finding that treatment of mice with a pharmacological inhibitor of the enzyme is lethal (Watson *et al.*, 2009). Most likely, the essentiality of Nam as NAD precursor is related to the fact that all NAD-dependent signaling pathways include NAD cleavage accompanied by the liberation of the Nam moiety (Figure 1). Consequently, NamPRT is critical to reutilize Nam for NAD biosynthesis. Therefore, the NAD biosynthetic route using Nam as precursor is also referred to as salvage pathway. In fact, considering the estimated daily NAD turnover, at least several grams of NAD precursors per day would be required to maintain organismal NAD levels (Chiarugi *et al.*, 2012). However, the daily recommended allowance (RDA) for vitamin B3 is only about 15 mg [Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, 1998]. These considerations indicate that Nam, liberated during NAD-dependent signaling, is nearly completely reutilized for the regeneration of NAD pools. This supposition is also in line with the unusually high affinity of NamPRT towards Nam ($K_M \sim 5$ nM, in the presence of ATP; Burgos & Schramm, 2008) which indicates that even minute amounts of Nam will be detected and converted to NMN.

Similar to the synthesis of other nucleotides, pyridine mononucleotides can also be generated by phosphorylation of the corresponding nucleosides (or ribosides) NR and NAR (Figure 1). While NR had long been known as a metabolic intermediate, only a decade ago its integral role in NAD metabolism was established by the identification of nicotinamide riboside kinases (NRKs) in yeast and humans (Bieganowski & Brenner, 2004). When cells are unable to metabolize NA or Nam, their viability and NAD pools can be fully maintained by supplementation with NR (Grozio *et al.*, 2013; Nikiforov *et al.*, 2011). In humans, NR is converted to NMN by NRK1 and 2 (Bieganowski & Brenner, 2004; Tempel *et al.*, 2007). In recent studies, a variety of health benefits has been reported that were the result of NR treatment. For example, in a mouse model of Alzheimer's disease, NR treatment significantly increased the NAD level in the cerebral cortex and improved cognitive function (Gong *et al.*, 2013). Moreover, NR protected from noise-induced hearing loss and spiral ganglia neurite degeneration in mice (Brown *et al.*, 2014). The nucleoside also prevented weight gain in mice challenged with a high-fat diet (Canto *et al.*, 2012). Similarly, dietary NR supplementation effectively

Figure 1. Overview of the NAD metabolome in humans. NAD can be synthesized from five precursors: tryptophan (Trp), the pyridine bases nicotinamide (Nam) and nicotinic acid (NA) or the nucleosides Nam riboside (NR) and NA riboside (NAR), which enter cells by different transport mechanisms. Quinolinic acid (QA), a Trp degradation product, is transformed to NA mononucleotide (NAMN) by quinolinic acid phosphoribosyltransferase (QAPRT). Nam and NA are converted to the corresponding mononucleotides (NMN and NAMN) by nicotinamide phosphoribosyltransferase (NamPRT, also known as NAMPT) and nicotinic acid phosphoribosyltransferase (NAPRT), respectively. NMN might also be synthesized by an extracellular NamPRT form (eNAMPT). NMN and NAMN are also generated through phosphorylation of NR and NAR, respectively, by nicotinamide riboside kinases (NRK). NAMN and NMN are converted to the corresponding dinucleotide (NAAD or NAD^+) by NMN adenylyltransferases (NMNAT). NAD synthetase (NADS) amidates NAAD to NAD^+. Phosphorylation by NAD kinase (NADK) converts NAD^+ to $NADP^+$. The oxidized and reduced forms of the dinucleotides, $NAD(P)^+$ and NAD(P)H, serve as reversible hydrogen carriers in redox reactions. Members of the Sirtuin family of protein deacetylases catalyze the transfer of the protein-bound acetyl group onto the ADP-ribose moiety, thereby forming O-acetyl-ADP ribose (OAcADPR). The transfer of a single (mono-ADP-ribosylation) or several (poly-ADP-ribosylation) ADP-ribose units from NAD^+ to acceptor protein is catalyzed by diphtheria toxin-like ADP-ribosyltransferases (ARTD). Mono-ADP-ribosylation is also catalyzed by clostridial toxin-like ADP-ribosyltransferases (ARTC) and some Sirtuin proteins. NAD^+ and $NADP^+$ are also used for the synthesis of second messengers, nicotinic acid adenine dinucleotide phosphate (NAADP), cyclic ADP-ribose (cADPR) and ADPR, which mediate intracellular calcium mobilization. All the three molecules are synthesized by ecto-NAD glycohydrolases CD38 and CD157. The mechanism of how messengers reach their cytosolic targets is still debated. Signaling-independent interconversions of NAD and its intermediates include NAD hydrolysis to NMN and AMP by Nudix pyrophosphatases (NUDT); NMN dephosphorylation to NR by cytosolic 5′-nucleotidases (5′-NT); phosphorolytic cleavage of NR to Nam by purine nucleoside phosphorylase (PNP); and conversion of Nam to N-methylnicotinamide (1-MNA) by nicotinamide-*N*-methyltransferase (NNMT). NAD^+ can possibly be released from cells through connexin 43 hemichannels (Cx43), and can be degraded to NR by ecto-nucleotidase CD73. NR is hydrolyzed to Nam by CD157. Whether cells can take up NAD or NMN is debated. (see colour version of this figure at www.informahealthcare.com/bmg).

delayed the progression of early and late stage mitochondrial myopathy, caused increased mitochondrial biogenesis and improved insulin sensitivity (Khan *et al.*, 2014). The beneficial action of NR on mitochondrial biology was further highlighted in a mouse model of mitochondrial disease characterized by impaired cytochrome c oxidase biogenesis. Supplementation with NR led to marked improvement of the respiratory chain defect and exercise intolerance (Cerutti *et al.*, 2014).

NAD biosynthesis from all known precursors merges at the step of dinucleotide formation (Figure 1). The reaction between the pyridine mononucleotide and ATP is carried out by NMN adenylyltransferases (NMNATs) resulting in the generation of NAD from NMN or NAAD (NA adenine dinucleotide) from NAMN. Interestingly, analyses of the subcellular location of enzymes involved in human NAD biosynthesis revealed that they all reside in the cytosol or nucleus, except for one of the three NMNAT isoforms, namely, NMNAT3 (Nikiforov *et al.*, 2011). NMNAT3 has been localized to the mitochondrial matrix and thereby represents the only NAD biosynthetic enzyme that is separated from the nucleo-cytosolic pool of intermediates. This finding suggested that mammalian mitochondria may have an autonomous route of NAD generation which, by deduction, would depend on the import of NMN from the cytosol. However, a mitochondrial carrier that mediates NMN import into the organelles has not been identified (Figure 2). Interestingly, besides being associated with the Golgi complex, NMNAT2 is associated with axonal vesicles and appears to have a critical role in the maintenance of axonal integrity (Conforti *et al.*, 2014).

To form NAD, amidation of the nicotinic acid moiety of NAAD is carried out by NAD synthetase, which uses glutamine as donor of the NH_2 group (Figure 1). NAD synthetase has also been localized to the cytosol suggesting that mitochondria can only use NMN as precursor to generate NAD. Indeed, it has been found that the mitochondrial NAD pool is rather sensitive to alterations of NamPRT activity (Nikiforov *et al.*, 2011; Yang *et al.*, 2007), the enzyme that directly generates NMN from Nam.

Research over the past 10–15 years has thus established that there are several routes which enable the use of alternative precursors to maintain intracellular NAD pools. Whether this redundancy is vital or whether it has, for example, tissue-specific significance still needs to be explored. Most of the enzymes involved have been scrutinized and important structural as well as regulatory properties have emerged from these studies (for more detailed analyses and comparisons, see, for example, these recent reviews (Dölle *et al.*, 2013b; Houtkooper *et al.*, 2010; Magni *et al.*, 2008, 2009). However, as indicated above, there are still open questions that need further research to be answered.


Figure 2. Subcellular compartmentalization of NAD pools. An outline of four subcellular NAD pools (nuclear/cytosolic, mitochondrial, peroxisomal and ER/Golgi) is shown. NAD(P)-dependent processes in each compartment are indicated in frames. Cytosolic and nuclear pools of NAD are combined based on the assumption that NAD can freely exchange between these two compartments. Nuclear/cytosolic and mitochondrial pools are maintained by NAD biosynthesis in these compartments. The three NMNAT isoforms catalyzing the generation of NAD from NMN are localized within the nucleus (NMNAT1), at the surface of the Golgi apparatus (NMNAT2) and within the mitochondria (NMNAT3). It is suggested that NMN is imported from the cytosol into the mitochondrial matrix, but the mechanism of this transport is unclear. The peroxisomal NAD pool can be maintained by import of the dinucleotide from the cytosol through the carrier protein SLC25A17. Peroxisomal NAD can be cleaved to AMP and NMN by Nudix hydrolase NUDT12. It is assumed that the generated NMN is released from the organelle to the cytosol through the PXMP2 channel. Although NAD(P)-dependent processes in ER have been identified, the mechanism of NAD supply to this organelle remains unknown. Moreover, a possible role of NAD in the Golgi lumen is obscure. (see colour version of this figure at www.informahealthcare.com/bmg).

NAD-dependent signaling

During the past two decades, the understanding of the biological roles of NAD has considerably changed. It is now beyond doubt that this dinucleotide is important not only for the cellular energy metabolism, but also represents a key molecule of cellular signaling being substrate for various regulatory proteins (Berger *et al.*, 2004; Houtkooper *et al.*, 2010). NAD-dependent post-translational protein modifications have decisive impact on vital processes including gene expression, cell cycle progression, insulin secretion, DNA repair, apoptosis, aging and many others (Haigis & Sinclair, 2010; Hassa & Hottiger, 2008; Koch-Nolte *et al.*, 2008). Moreover, NAD is the biosynthetic precursor of metabolites that mediate intracellular calcium mobilization (Fliegert *et al.*, 2007). As a result of all signaling conversions of NAD, the molecule is cleaved into nicotinamide and an ADP-ribose derivative (Figure 1). Therefore, NAD-dependent signaling processes are also referred to as ADP-ribosyl transfer reactions. Eventually, all ADP-ribosyl derivatives are converted to ADP-ribose, which, in turn, can be further degraded, for example, to AMP and ribose-5-phosphate (Formentini *et al.*, 2009a).

NAD-dependent deacetylation

NAD-dependent deacetylation of various protein substrates is performed by members of the highly conserved family of silent information regulator-2 (Sir2) like proteins (Sirtuins). Sirtuins have been found in all living organisms from bacteria to man (Brachmann *et al.*, 1995).

In the course of the deacetylation reaction, nicotinamide is cleaved off and the protein-bound acetyl group is transferred onto the ADP-ribose moiety, thereby forming O-acetyl-ADP ribose (OAADPR) (Jackson & Denu, 2002; Tanner *et al.*, 2000).

In humans, seven members of the Sirtuin family have been characterized (SIRT1-7). SIRT1, 6 and 7 are located in the nucleus, SIRT2 has been found both in the nucleus and cytosol, while SIRT3, 4 and 5 are mitochondrial proteins (Michishita *et al.*, 2005), even though for SIRT3 nuclear functions have also been proposed (Iwahara *et al.*, 2012; Scher *et al.*, 2007). Besides a deacetylase activity, some Sirtuins also display other catalytic activities. It was shown that SIRT6 exhibits both deacetylase and ADP-ribosyltransferase activities (Mao *et al.*, 2011; Michishita *et al.*, 2008), SIRT4 was found to have only ADP-ribosyltransferase activity (Haigis *et al.*, 2006), whereas SIRT5 may act as a lysine demalonylase and desuccinylase (Du *et al.*, 2011).

Originally, Sirtuins were described as NAD-dependent histone deacetylases which mediate transcriptional silencing and longevity (Imai *et al.*, 2000; Landry *et al.*, 2000; Smith *et al.*, 2000). Later, it was demonstrated that, besides histones, Sirtuins deacetylate a broad spectrum of protein substrates including regulatory, structural and catalytically active proteins (Martinez-Redondo & Vaquero, 2013). NAD-dependent deacetylation results in the modulation of target protein activity, stability or localization thereby regulating aging, transcription, cell cycle progression, genome stability, apoptosis, mitochondrial biogenesis and many other vital processes (Haigis & Sinclair, 2010). It is important to emphasize the critical role of Sirtuins in the regulation of metabolism. Since these enzymes use NAD^+ as a co-substrate, their activity is dependent on the bioenergetic state of the cell (which is, in part, reflected by the NAD^+/NADH ratio and the overall NAD concentration). That is, Sirtuins directly link the metabolic state with signaling processes and thereby also regulate the cellular response to environmental signals (Chang & Guarente, 2014; Houtkooper *et al.*, 2012). The biological role of OAADPR, a product of the Sirtuin reactions, is still unclear. However, evidence has been presented suggesting that this molecule could be a ligand of calcium channels in the plasma membrane, such as TRPM2 channels (Grubisha *et al.*, 2006). This possibility would establish a mechanistic link between protein acetylation state and calcium signaling. OAADPR has been shown to be cleaved to ADPR by ADP-ribosyl-acceptor hydrolase 3 (ARH3) (Kasamatsu *et al.*, 2011; Ono *et al.*, 2006), an enzyme that is also involved in poly-ADP-ribose metabolism.

ADP-ribosylation

Another mechanism of NAD-dependent protein modification is ADP-ribosylation. This reaction mediates the transfer of a single (mono-ADP-ribosylation) or several (poly-ADP-ribosylation) ADP-ribose units from NAD^+ to specific amino acids of acceptor proteins. As a result of poly-ADP-ribosylation, polymers of ADP-ribose are attached to acceptor proteins. These polymers can be branched and consist of up to 200 ADP-ribose units (Bürkle, 2005). ADP-ribosylation is catalyzed by two families of enzymes: clostridial toxin-like ADP-ribosyltransferases (ARTC) and diphtheria toxin-like ADP-ribosyltransferases (ARTD) (Hottiger *et al.*, 2010) (Figure 1). So far, five mammalian members of the ARTC family have been described. They are ectoenzymes which catalyze mono-ADP-ribosylation of secreted and membrane proteins, as well as cell surface receptors, and thus can regulate innate immunity and cell–cell and cell–matrix interactions (Koch-Nolte *et al.*, 2008; Seman *et al.*, 2004). Members of the ARTD family (currently including 18 mammalian proteins) catalyze mono- or poly-ADP-ribosylation inside the cell (Hottiger *et al.*, 2010). In addition to the ARTDs and the ARTCs, Sirtuins SIRT4 and SIRT6 are able to mono-ADP-ribosylate proteins (Haigis *et al.*, 2006; Mao *et al.*, 2011).

Intracellular mono- and poly-ADP-ribosylation has been shown to be involved in many essential cellular processes including: DNA repair, apoptosis, transcription, cell cycle progression, energy metabolism and many others. For many of these functions, the molecular mechanisms have been explored. These functions have been reviewed in detail in several excellent recent articles (Bürkle & Virag, 2013; Feijs *et al.*, 2013; Grimaldi *et al.*, 2015; Hassa & Hottiger, 2008).

Since ADP-ribosylation participates in the regulation of important cellular processes, its extent needs to be tightly controlled. Indeed, as other post-translational modifications, both mono- and poly-ADP-ribosylation are reversible. It was shown that ADP-ribosyl-acceptor hydrolase 1 (ARH1) hydrolyses the *N*-glycosidic bond linking ADP-ribose to an arginine residue of the modified protein (Moss *et al.*, 1992). On the other hand, poly-ADP-ribose glycohydrolase (PARG) and

ADP-ribosyl-acceptor hydrolase 3 (ARH3) cleave the O-glycosidic bond of poly-ADP-ribose chains (Lin *et al.*, 1997; Mashimo *et al.*, 2013; Mueller-Dieckmann *et al.*, 2006; Niere *et al.*, 2012; Oka *et al.*, 2006; Slade *et al.*, 2011), while the remaining ADP-ribose, linked to glutamate residues, is removed by specialized enzymes – MacroD1, MacroD2 and terminal ADP-ribose protein glyco-hydrolase 1 (TARG1) (Jankevicius *et al.*, 2013; Rosenthal *et al.*, 2013; Sharifi *et al.*, 2013). These processes lead to release of ADP-ribose and the regeneration of the unmodified protein.

Calcium mobilization

NAD(P)$^+$-derived molecules are now also well established as key elements of intracellular calcium signaling. Several of these derivatives, namely, nicotinic acid adenine dinucleotide phosphate (NAADP), cyclic ADP-ribose (cADPR) and ADPR have been characterized as potent calcium-mobilizing agents (Gasser *et al.*, 2006; Lee *et al.*, 1989; Lee & Aarhus, 1995) (Figure 1). The calcium mobilization systems activated by NAD(P) derivatives have been broadly addressed. Both cADPR and NAADP stimulate calcium release from endogenous stores. While cADPR activates ryanodine receptors, thereby stimulating calcium release from the endoplasmic reticulum, NAADP activates two-pore channels which have been found in endolysosomes (Galione, 2014; Guse, 2014; Lee, 2012; Patel *et al.*, 2010). On the other hand, ADPR can trigger calcium entry from the extracellular space via activation of plasma membrane cation channel TRPM2 (Guse, 2014; Sumoza-Toledo & Penner, 2011). All three molecules, ADPR, cADPR and NAADP are synthesized by multifunctional NAD glycohydrolases, in humans represented by the ecto-ADP-ribosyl cyclase CD38 and its structural and functional homolog, CD157 (Malavasi *et al.*, 2008) (Figure 1). Besides the synthesis, these proteins also catalyze the hydrolysis of cADPR to ADPR. NAADP is generated by exchanging nicotinamide for nicotinic acid in NADP$^+$. Since the catalytic activity of CD157 is by far less compared to that of CD38 (Malavasi *et al.*, 2008), the biological role of CD157 is not well understood.

No other (intracellular) mammalian NAD glycohydrolases have been identified so far. Moreover, many of the intracellular calcium signaling events mediated by NAD derivatives have been ascribed to CD38 activity. Given that CD38 is an ectoenzyme, it has remained difficult to explain these intracellular effects. This has been referred to as the topological paradox of CD38. That is, CD38 being a type II transmembrane protein with its active site facing the extracellular space, seems to produce messengers that are used for intracellular calcium signaling. It is also not entirely clear, how the presence of its substrates, NAD$^+$ and NADP$^+$, in the extracellular space is mediated and regulated. A variety of studies have been conducted to address these issues. De Flora and co-workers showed that NAD can be released from various types of cells through connexin 43 (Cx43) hemi-channels (Bruzzone *et al.*, 2001; Fruscione *et al.*, 2011; Verderio *et al.*, 2001). It was also observed that one of the second messengers, cADPR, can enter the cell via nucleoside transporters (Podesta *et al.*, 2005) or by channeling across oligomeric CD38 (Franco *et al.*, 1998). Further observations led to the suggestion that Cx43 has a dual function exporting NAD and importing cADPR into the cell (Song *et al.*, 2011).

Despite these efforts, a conclusive mechanism explaining the topological paradox of CD38 is still lacking. It was proposed that intracellular vesicles containing CD38 could arise from endocytosis. If NAD or NADP were present or transported into these vesicles, the calcium messengers could be released upon stimulation (Zocchi *et al.*, 1999). Such a mechanism was demonstrated for cADPR-dependent calcium mobilization in sea urchin eggs (Davis *et al.*, 2008). Recently, an interesting alternative explanation was presented. It was shown that CD38 could be expressed as type III transmembrane protein. The resultant protein would be fully active and could therefore produce cADPR in the cytosol (Zhao *et al.*, 2012, 2014). Nevertheless, the mechanism how these metabolites are produced and accessible within the cytoplasm still remains to be established.

Recycling of NAD degradation products

Nam and ADPR are the common products generated as a result of NAD-dependent signaling conversions. In human cells, ADPR can be cleaved by several members of the Nudix hydrolase family (McLennan, 2006). Among these enzymes, NUDT9 appears to have the highest specificity towards ADPR. It was therefore suggested that NUDT9 may be responsible for ADP-ribose elimination by its splitting to AMP and ribose 5-phosphate (Lin *et al.*, 2002; Perraud *et al.*, 2001, 2003). The reutilization of the degradation products arising from NAD-dependent signaling would require three molecules of ATP to regenerate NAD. Therefore, NAD-dependent signaling events, especially poly-ADP-ribosylation, are energetically rather expensive adding further weight to their functional roles.

Taken together, NAD-dependent signaling pathways comprise a complex network of regulatory mechanisms. Different pathways ''compete'' for the same substrate, NAD$^+$, whose intracellular concentration is tightly regulated. Therefore, even though NAD availability is an important factor in the coordination of NAD-dependent signaling, the interrelationships between different pathways are likely governed by additional mechanisms.

Intracellular degradation and interconversion of NAD and its metabolites

Degradation of NAD to NMN

In prokaryotes and lower eukaryotes, the intracellular NAD concentration is regulated through both biosynthesis and enzymatic cleavage to NMN and AMP by pyrophosphatases of the Nudix family. Nudix (nucleoside diphosphate linked to moiety X) hydrolases or pyrophosphatases are found in all the types of organisms, from archaea to mammals. The substrates of these enzymes (NDP-X) comprise molecules consisting of a nucleoside diphosphate (NDP) linked to various other moieties (X). Well-characterized substrates include (d)NTPs, dinucleoside polyphosphates (Np$_n$N), NAD and capped RNAs. When the pyrophosphate bond is cleaved, the

corresponding mononucleotide (NMP) and the phosphorylated compound X (P-X) are generated. Nudix pyrophosphatases control the levels of metabolites and signaling molecules and cleave potentially mutagenic, oxidized nucleotides (McLennan, 2006).

The bacterial protein YjaD was the first Nudix pyrophosphatase shown to cleave NAD (Frick & Bessman, 1995; McLennan, 2006). Recently, a fungal pyrophosphatase, NdxA, was identified. This protein controls the intracellular NAD^+ and NADH levels in *Aspergillus nidulans*, thereby regulating important NAD-dependent processes such as gene expression and glycolysis. Due to its ability to cleave NAD, NdxA negatively regulates the NAD-dependent protein deacetylase SirA, which requires NAD^+ as a co-substrate for histone H4 deacetylation. In turn, the downregulation of SirA leads to diminished expression of several genes (Shimizu *et al.*, 2012). NAD degradation by NdxA also has an impact on the utilization of pyruvate and intermediates of the tricarboxylic acid cycle (Shimizu & Takaya, 2013).

In the human genome, 24 genes have been detected that encode Nudix hydrolases with different substrate specificity. The mammalian NUDT12 protein exhibits the highest similarity to the bacterial YjaD and the fungal NdxA enzymes. Moreover, NUDT12 contains the consensus sequence SQPWPFPxS, found in the conserved Nudix domain, which is present in all NAD pyrophosphatases identified until now (Abdelraheim *et al.*, 2003; McLennan, 2006). However, so far, little is known about the substrate specificity and functions of NUDT12. It was shown that NUDT12 efficiently cleaves NADH, NADPH and NAD^+ *in vitro*. Moreover, the PNL sequence at the C-terminus mediates its peroxisomal localization (Figure 2), (Abdelraheim *et al.*, 2003). NUDT12 could therefore regulate the levels of NAD and NADP in these organelles.

Degradation of NMN to NR

In yeast cells, the mononucleotides NMN and NAMN can be dephosphorylated to NR and NAR by the cytosolic 5′-nucleotidases Isn1 and Sdt1 and the vacuolar phosphatase Pho8 (Bogan *et al.*, 2009; Lu & Lin, 2011). In general, 5′-nucleotidases dephosphorylate both purine and pyrimidine ribo- and deoxyribo-mononucleotides to their corresponding nucleosides, thereby controlling major nucleotide metabolic pathways (Hunsucker *et al.*, 2005; Ipata & Balestri, 2013). These enzymes are characterized by rather broad substrate specificity. Indeed, before their identification as NMN and NAMN cleaving enzymes, Isn1 and Sdt1 were characterized as IMP- and pyrimidine mononucleotide-specific 5′-nucleotidases, respectively (Itoh *et al.*, 2003; Nakanishi & Sekimizu, 2002).

In humans, three cytosolic 5′-nucleotidases have been described, CN-IA, CN-II and CN-III (Hunsucker *et al.*, 2005). They exhibit different substrate specificities. It has been proposed that these enzymes might mediate the generation of NR or NAR in human cells using NMN or NAMN, respectively, as substrate (Bogan & Brenner, 2010; Magni *et al.*, 2004). However, experimental evidence for such a possibility is lacking.

Degradation of NR to Nam

Besides the utilization by nicotinamide riboside kinase 1 (Nrk1) to form NMN, in yeast cells NR can also be cleaved to Nam (which then can enter an alternative NAD-biosynthetic route). Three enzymes were identified (Urh1, Pnp1 and Meu1) which catalyze this cleavage, however, using two different mechanisms. Urh1 is a nucleoside hydrolase leading to the formation of Nam and ribose, whereas both Pnp1 and Meu1 are nucleoside phosphorylases generating Nam and ribose-1-phosphate from NR (Belenky *et al.*, 2007b, 2009; Ma *et al.*, 2007).

In humans, the phosphorolytic cleavage of NR to Nam was shown more than half a century ago (Grossman & Kaplan, 1958; Rowen & Kornberg, 1951). However, the mammalian enzyme capable of catalyzing this conversion was only recently identified as purine nucleoside phosphorylase (PNP) (Wielgus-Kutrowska *et al.*, 1997) (Figure 1). PNP has been known to catalyze the reversible phosphorolytic cleavage of purine oxy- and deoxynucleosides (Moriwaki *et al.*, 1999). Even though the biochemical *in vitro* characterization of bovine PNP revealed that NR is far less preferred as substrate than, for example, inosine (Belenky *et al.*, 2009; Wielgus-Kutrowska *et al.*, 1997), its heterologous expression in yeast demonstrated its capacity to substitute the yeast homolog Pnp1 to mediate NAD synthesis from Nam generated by NR cleavage (Belenky *et al.*, 2009).

The functional relevance of NR degradation to Nam still remains to be established. It is still unclear whether this conversion represents a mechanism necessary as alternative for NR utilization by NRKs or whether it has other, for example, regulatory functions. The reversibility of the phosphorolytic NR cleavage is another, quite intriguing aspect. Given the presence of ribose-1-phosphate in human cells, Nam could be converted to NR to enter NAD biosynthesis. However, a major contribution of such a pathway appears rather unlikely, because inhibition of NamPRT, which catalyzes NMN formation from Nam, causes death in a large variety of cell types.

Conversion of Nam to 1-MNA

The cytosolic enzyme nicotinamide-N-methyltransferase (NNMT) catalyzes the formation of N-methylnicotinamide (1-MNA) using S-adenosylmethionine (SAM) as methyl donor (Figure 1); (Aksoy *et al.*, 1994; Cantoni, 1951). The involvement of SAM, the universal methyl group donor, which is also used for the methylation of proteins and nucleic acids (Jia *et al.*, 2011; Lu, 2000; Luo, 2012; Ulrey *et al.*, 2005) represents an intriguing link between gene regulation and epigenetics and NAD metabolism. For many years, this conversion was regarded as a catabolic pathway merely mediating the excretion of excess Nam. This notion has dramatically changed over the past few years. Elevation of NNMT expression has been observed in neurodegenerative diseases (Williams *et al.*, 2005), obesity and diabetes type II (Kraus *et al.*, 2014; Lee *et al.*, 2005; Yaguchi *et al.*, 2005). Moreover, NNMT is strongly increased in a variety of tumors and has been proposed to support tumorigenesis by promoting migration, invasion and proliferation of cancer

cells (Roessler *et al.*, 2005; Sartini *et al.*, 2013; Tang *et al.*, 2011; Ulanovskaya *et al.*, 2013; Wu *et al.*, 2008).

Exploration of the mechanisms leading to these phenomena has led to several ground-breaking discoveries. It was shown that increased expression of NNMT lowers the cellular concentration of SAM (the universal methyl group donor) thereby causing a deficiency of methyl groups in other pathways. In turn, a decrease of specific histone methylation was demonstrated leading to a shift in the epigenetic state. It was proposed that the conversion of Nam to 1-MNA could thereby act as a stable sink to store methyl groups in cancer cells (Ulanovskaya *et al.*, 2013).

In another study, it was found that the NNMT reaction does not only regulate the level of SAM in adipose tissue, but also has an impact on the cellular NAD concentration. In obese mice with diabetes type II, NNMT expression was increased in both white adipose tissue and the liver. Consequently, both SAM and NAD levels were diminished, leading to hypomethylation of histones, lowered polyamine synthesis and suppression of SIRT1-dependent signaling. On the other hand, the authors demonstrated that knockdown of NNMT prevented the development of obesity in animals fed with a high-fat diet (Kraus *et al.*, 2014).

These recent insights into the functional consequences of altered NNMT activity suggest that Nam potentially has a critical role not only for the synthesis of NAD, but also in the regulation of pathways seemingly unrelated to NAD metabolism.

Extracellular NAD metabolites and their degradation

Extracellular NAD

Under normal physiological conditions, the extracellular concentration of NAD (e.g. in blood plasma) has been reported to be in the submicromolar range (Kim *et al.*, 1993; O'Reilly & Niven, 2003). Extracellular NAD could be the result of cell lysis. However, stressed cells can actively release NAD. For example, in a mouse model of inflammation induced by injection of polyacrylamide beads, NAD$^+$ was released as an early response and its extracellular concentration reached 10 μM (Adriouch *et al.*, 2007). It has also been shown that NAD is released from various types of neuronal cells upon stimulation to serve as a novel neurotransmitter and neuromodulator (Breen *et al.*, 2006; Mutafova-Yambolieva *et al.*, 2007; Smyth *et al.*, 2004). It has also been shown that extracellular NAD can regulate functions of human granulocytes and mesenchymal stem cells by activation of P2Y11 receptor (Fruscione *et al.*, 2011; Moreschi *et al.*, 2006). Moreover, in mice NAD activates P2X7 receptor through ART2.2-mediated mono-ADP-ribosylation and thus induces apoptosis of T cells (Adriouch *et al.*, 2007, 2008; Seman *et al.*, 2003).

Extracellular degradation of NAD to NR

There are several studies demonstrating that extracellular NAD, and also NMN, can be used to maintain intracellular NAD levels. However, the mechanism is still debated. The direct uptake of the nucleotides has been suggested (Billington *et al.*, 2008; Durnin *et al.*, 2012;

Formentini *et al.*, 2009b; Pittelli *et al.*, 2011). Given that, except for connexin 43 hemichannels (Bruzzone *et al.*, 2001), no transporter has been identified, alternative mechanisms have been studied. It has recently been found that, in order to contribute to intracellular pools, extracellular NAD needs to be cleaved to NMN, which, in turn, is cleaved to NR. NR can then be taken up by membrane transporters, which have pharmacological characteristics known for identified nucleoside transporters present in the plasma membrane (Nikiforov *et al.*, 2011). This conclusion was further supported by the demonstration that the ectoenzyme CD73 successively degrades NAD to NMN and AMP and further to NR and adenosine (Garavaglia *et al.*, 2012; Grozio *et al.*, 2013) (Figure 1).

Extracellular degradation of NR to Nam

A recent study revealed that the conversion of NR to Nam takes place not only inside cells, but also at the cell surface. It was shown that the human CD157, known as an ecto-NAD glycohydrolase, cleaves the nucleosides NAR and NR to the corresponding bases, NA and Nam, and ribose (Preugschat *et al.*, 2014). Interestingly, the efficiency of CD157 to generate ADPR or cADPR from NAD is very low (>100 times lower than that of CD38; Malavasi *et al.*, 2008). On the other hand, the now discovered activity to cleave NR by far exceeds that of NAD cleavage. Moreover, the affinity of CD157 towards NR is extremely high ($K_M = 6$ nM) suggesting a highly specific mechanism. The molecular mechanism of the reaction was found to proceed via a long-lived intermediate state consisting of the ribosylated enzyme. A high level of this intermediate could also be observed in the presence of low NR concentrations. Based on these findings, it was suggested that extracellular NR could act as an activator of the receptor functions borne by CD157 (Preugschat *et al.*, 2014).

Extracellular NMN and NamPRT

There have been several studies demonstrating impressive health benefits from NMN supplementation (e.g. by injection into mice; Revollo *et al.*, 2007; Yamamoto *et al.*, 2014; Yoshino *et al.*, 2011). However, the physiological occurrence of extracellular NMN has still remained a matter of discussion. It appears unlikely that significant extracellular amounts of this nucleotide can arise as a result of cell damage, because the intracellular concentration was measured to be only around 1 μM (Trammell & Brenner, 2013). However, the possibility exists that NMN could be synthesized in plasma owing to the presence of an extracellular form of NamPRT (eNAMPT) (Revollo *et al.*, 2007), previously identified as pre-B cell colony enhancing factor (PBEF) (Samal *et al.*, 1994) and also as adipocytokine visfatin (Fukuhara *et al.*, 2005). It has been proposed that eNAMPT possesses signaling functions in adipocytes and pancreatic β-cells (Garten *et al.*, 2009).

Cellular compartmentalization of NAD

It is still widely believed that NAD is readily available in the nucleus/cytosol and mitochondria, because the overwhelming

majority of both the known bioenergetic and NAD-dependent signaling processes are found there. However, recent research has discovered an unexpected distribution of subcellular NAD pools, with readily detectable NAD in the mitochondria, peroxisomes and even in the ER and Golgi complex, that is, all cytoplasmic organelles tested by the PARAPLAY method, which is based on the formation of poly-ADP-ribose by targeted expression of the catalytic domain of PARP-1 (Dölle *et al.*, 2010). At least for the Golgi, no functional role of NAD has so far been identified. Moreover, given the subcellular distribution of NAD biosynthetic enzymes in mammalian cells NAD can only be synthesized in the nucleus/cytosol or mitochondria (Nikiforov *et al.*, 2011). A mammalian transporter for NAD has only been described for the peroxisomal membrane (Agrimi *et al.*, 2012). Therefore, it has remained largely unclear how organellar NAD pools are generated and maintained.

A large proportion of NAD-dependent processes is located in the nucleus and the cytosol. Even though there is no conclusive experimental evidence, it is widely believed that the nuclear membrane does not constitute a diffusion barrier for NAD and consequently it is assumed that the nucleotide can freely exchange between these two compartments. Therefore, with regard to NAD compartmentalization, the nucleus and cytosol have not been separated (Figure 2). It is also interesting to note that all enzymes of human NAD biosynthesis, except for the mitochondrial NMNAT3, have been localized to the nucleus or cytosol (Nikiforov *et al.*, 2011). Therefore, NAD can be readily regenerated in these compartments.

Mitochondrial NAD

In some tissues, mitochondria contain up to 70% of the total cellular NAD (Alano *et al.*, 2007; Stein & Imai, 2012). Mitochondrial NAD is a vital redox coenzyme for metabolic processes such as the tricarboxylic acid cycle, fatty acid oxidation and oxidative phosphorylation.

In recent years, it was also shown that NAD^+ has roles as a signaling molecule in the mitochondrial matrix, because it is an obligatory co-substrate for SIRT3, 4 and 5. These Sirtuins regulate the activities of key metabolic enzymes including glutamate dehydrogenase, acetyl-CoA synthetase 2, hydroxymethylglutaryl-CoA synthetase 2 and carbamoyl-phosphate synthetase 1 by deacetylation, deacylation or ADP-ribosylation (Dölle *et al.*, 2013a). As a result of these NAD-dependent post-translational modifications the dinucleotide is degraded. Therefore, the mitochondrial NAD pool needs to be continuously replenished.

Even though the mitochondrial inner membrane itself is impermeable for polar molecules, a large number of carrier proteins have been identified that mediate the exchange of solutes between the cytosol and the mitochondrial matrix (Palmieri, 2013). In yeast, the mitochondrial NAD pool is maintained by means of import of the nucleotide from the cytosol through the carrier proteins Ndt1p and Ndtp2 (Todisco *et al.*, 2006). A similar mechanism has been identified for mitochondria from *A. thaliana* (Palmieri *et al.*, 2009). In mammalian cells, however, the situation appears to be rather different. A direct exchange of NAD

between the mitochondrial matrix and the cytosol in human cells could not be detected (Yang *et al.*, 2007). Moreover, experiments using isolated rat liver mitochondria also indicated that there is no exchange of NAD across the mitochondrial inner membrane (Barile *et al.*, 1996). It was also found that the closest human homolog of the yeast carrier Ndt1p, the solute carrier protein SLC25A32, did not mediate the transport of NAD (Yang *et al.*, 2007). These observations suggested that, in mammalian cells, the mitochondrial NAD pool is segregated from the cytosolic one and needs to be replenished by autonomous generation of NAD. Even though progress has been made in this regard over the past few years, the exact molecular mechanisms how mitochondrial NAD is generated in human mitochondria still need to be established.

In a recent study, it was shown that all four vitamin B3 precursors (Nam, NA, NR and NAR) can enter human cells and support the generation of mitochondrial NAD (Nikiforov *et al.*, 2011). Moreover, among all known enzymes contributing to NAD biosynthesis, only NMNAT3 was found to be intramitochondrial, one of the three adenylyltransferases that convert NMN to NAD. The observation that increased generation of cytosolic NMN also leads to an increased mitochondrial NAD content further suggested that the mechanism of NAD generation in these organelles includes the import of NMN and its subsequent conversion to NAD by NMNAT3 (Figure 2) (Nikiforov *et al.*, 2011). However, so far, no carrier protein mediating the import of NMN has been identified. This identification has therefore remained as one of the most critical tasks to fully understand how the mitochondrial NAD pool is maintained in mammalian cells.

Peroxisomal NAD

Several NAD-dependent processes have been reported to be localized within peroxisomes including redox reactions catalyzed by enzymes of the fatty acid oxidation pathway, lactate dehydrogenase (LDH) and glycerol-3-phosphate dehydrogenase (G3PDH) (Wanders & Waterham, 2006). While NAD^+ is reduced to NADH during β-oxidation, both LDH and G3PDH re-oxidize NADH to NAD^+.

It has been shown that the peroxisomal membrane is partially permeable for metabolites (Antonenkov & Hiltunen, 2012; Antonenkov *et al.*, 2004). Solutes with a molecular mass up to ∼300 Da can freely diffuse through the Pxmp2 channels. However, bulkier molecules such as ATP, CoA and NAD are unable to pass through the peroxisomal membrane in the absence of carrier proteins (Rokka *et al.*, 2009). SLC25A17 was shown to transport CoA, FAD, FMN, AMP and to lesser extent NAD^+ and ADP by an exchange mechanism (Agrimi *et al.*, 2012). As indicated above, peroxisomal NAD can be cleaved to AMP and NMN by NUDT12 (Abdelraheim *et al.*, 2003). Therefore, NUDT12 could be important to regulate the NAD content in these organelles. Because mouse Pxmp2 mediated the release of AMP (Antonenkov & Hiltunen, 2012; Rokka *et al.*, 2009), the generated NMN could possibly be released from the peroxisomes through this channel. NMN could then be used by NMNAT1 or 2 to regenerate NAD (Figure 2). In this scenario, the peroxisomal NAD pool could serve as a buffer to maintain a constant free NAD level in the cytosol.

NAD in the ER and the Golgi complex

The presence of NAD^+ within the ER and the Golgi complex has been demonstrated using the PARAPLAY assay (Dölle et al., 2010). However, the biological role of NAD in these organelles is unclear. No NAD-dependent process within the Golgi complex is known. In the ER, the luminal chaperone glucose-regulated protein 78 (GRP78), also known as immunoglobulin heavy chain-binding protein (BiP), is regulated by NAD-dependent mono-ADP-ribosylation. GRP78/BiP mediates translocation of the newly synthesized proteins from the ribosome to the ER and their correct folding in the ER lumen. Moreover, GRP78/BiP targets misfolded proteins for ER-associated protein degradation and plays a key role in the unfolded protein response (Schroder & Kaufman, 2005). When induced by various stress conditions, mono-ADP-ribosylation inactivates GRP78/BiP leading to intensification of ER stress signaling (Chambers et al., 2012; Fabrizio et al., 2015; Leno & Ledford, 1989). Recently, human ecto-ADP-ribosyltransferase ARTC1 was shown to localize to the ER lumen and to mono-ADP-ribosylate GRP78/BiP in response to ER stress (Fabrizio et al., 2015).

There have also been reports suggesting an independent NADP pool in the ER (Bublitz & Lawler, 1987; Piccirella et al., 2006). Indeed, two enzymes which require NADP have been localized to the lumen of the ER, namely, hexose-6-phosphate dehydrogenase (H6PD) and 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). H6PD catalyzes the first two steps of the pentose phosphate pathway in which glucose-6-phosphate is oxidized to 6-phosphogluconate accompanied by the reduction of $NADP^+$ to NADPH (Senesi et al., 2010). NADPH, in turn, is required for the conversion of cortisone to cortisol catalyzed by 11β-HSD1 (Banhegyi et al., 2004; Chapman et al., 2013).

Conclusions and future perspectives

Recent research has revealed the importance of the regulatory roles of NAD. In fact, some of these pathways have already been targeted for therapeutic treatments of cancer and other diseases. While impressive progress has been made over the last years with regard to NAD-dependent signaling mechanisms, some critical issues have remained unresolved. For example, NAD-dependent signaling uses up an unexpectedly large amount of NAD. Therefore, NAD biosynthesis has to be highly active and needs to be fine-tuned to the actual demands of the cell. However, except for the identification of the principal pathways of NAD biosynthesis and the corresponding enzymes, surprisingly little is known about the mechanisms regulating NAD synthesis and how it influences signaling pathways. Moreover, cellular NAD is compartmentalized in distinct membrane-coated organelles in human cells. Yet, almost nothing is known about whether (and how) NAD enters these organelles or is produced there. In this regard more detailed insights into the interconversions of NAD metabolites will likely facilitate understanding the maintenance of individual NAD pools. It appears as an intriguing possibility that the compartmentalization might represent a means to selectively influence NAD-dependent signaling events. The tremendous medical relevance as well as the broad scientific interest in this field will promote further research into these and other exciting questions regarding NAD biology.

References

Abdelraheim SR, Spiller DG, McLennan AG. (2003). Mammalian NADH diphosphatases of the Nudix family: cloning and characterization of the human peroxisomal NUDT12 protein. Biochem J 374: 329–35.

Adriouch S, Hubert S, Pechberty S, et al. (2007). NAD + released during inflammation participates in T cell homeostasis by inducing ART2-mediated death of naive T cells in vivo. J Immunol 179:186–94.

Adriouch S, Bannas P, Schwarz N, et al. (2008). ADP-ribosylation at R125 gates the P2X7 ion channel by presenting a covalent ligand to its nucleotide binding site. FASEB J 22:861–9.

Agrimi G, Russo A, Scarcia P, et al. (2012). The human gene SLC25A17 encodes a peroxisomal transporter of coenzyme A, FAD and NAD+. Biochem J 443:241–7.

Aksoy S, Szumlanski CL, Weinshilboum RM. (1994). Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J Biol Chem 269:14835–40.

Alano CC, Tran A, Tao R, et al. (2007). Differences among cell types in NAD(+) compartmentalization: a comparison of neurons, astrocytes, and cardiac myocytes. J Neurosci Res 85:3378–85.

Antonelli A, Ferrannini E. (2004). CD38 autoimmunity: recent advances and relevance to human diabetes. J Endocrinol Invest 27:695–707.

Antonenkov VD, Sormunen RT, Hiltunen JK. (2004). The rat liver peroxisomal membrane forms a permeability barrier for cofactors but not for small metabolites in vitro. J Cell Sci 117:5633–42.

Antonenkov VD, Hiltunen JK. (2012). Transfer of metabolites across the peroxisomal membrane. Biochim Biophys Acta 1822:1374–86.

Bahn A, Hagos Y, Reuter S, et al. (2008). Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J Biol Chem 283:16332–41.

Banhegyi G, Benedetti A, Fulceri R, et al. (2004). Cooperativity between 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the lumen of the endoplasmic reticulum. J Biol Chem 279:27017–21.

Barile M, Passarella S, Danese G, et al. (1996). Rat liver mitochondria can synthesize nicotinamide adenine dinucleotide from nicotinamide mononucleotide and ATP via a putative matrix nicotinamide mononucleotide adenylyltransferase. Biochem Mol Biol Int 38: 297–306.

Belenky P, Bogan KL, Brenner C. (2007a). NAD^+ metabolism in health and disease. Trends Biochem Sci 32:12–19.

Belenky P, Racette FG, Bogan KL, et al. (2007b). Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell 129:473–84.

Belenky P, Christensen KC, Gazzaniga F, et al. (2009). Nicotinamide riboside and nicotinic acid riboside salvage in fungi and mammals. Quantitative basis for Urh1 and purine nucleoside phosphorylase function in NAD^+ metabolism. J Biol Chem 284:158–64.

Berger F, Ramirez-Hernandez MH, Ziegler M. (2004). The new life of a centenarian: signalling functions of NAD(P). Trends Biochem Sci 29: 111–18.

Bieganowski P, Brenner C. (2004). Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD + in fungi and humans. Cell 117:495–502.

Billington RA, Travelli C, Ercolano E, et al. (2008). Characterization of NAD uptake in mammalian cells. J Biol Chem 283:6367–74.

Bogan KL, Brenner C. (2008). Nicotinic acid nicotinamide and nicotinamide riboside: a molecular evaluation of NAD(+) precursor vitamins in human nutrition. Annu Rev Nutr 28:115–30.

Bogan KL, Evans C, Belenky P, et al. (2009). Identification of Isn1 and Sdt1 as glucose- and vitamin-regulated nicotinamide mononucleotide and nicotinic acid mononucleotide [corrected] 5′-nucleotidases

responsible for production of nicotinamide riboside and nicotinic acid riboside. J Biol Chem 284:34861–9.

Bogan KL, Brenner C. (2010). 5′-Nucleotidases and their new roles in NAD + and phosphate metabolism. New J Chem 34:845–53.

Brachmann CB, Sherman JM, Devine SE, et al. (1995). The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev 9:2888–902.

Breen LT, Smyth LM, Yamboliev IA, et al. (2006). Beta-NAD is a novel nucleotide released on stimulation of nerve terminals in human urinary bladder detrusor muscle. Am J Physiol Renal Physiol 290: F486–95.

Brown KD, Maqsood S, Huang JY, et al. (2014). Activation of SIRT3 by the NAD(+) precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab 20:1059–68.

Bruzzone S, Guida L, Zocchi E, et al. (2001). Connexin 43 hemi channels mediate Ca^{2+}-regulated transmembrane NAD + fluxes in intact cells. FASEB J 15:10–12.

Bublitz C, Lawler CA. (1987). The levels of nicotinamide nucleotides in liver microsomes and their possible significance to the function of hexose phosphate dehydrogenase. Biochem J 245:263–7.

Burgos ES, Schramm VL. (2008). Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase. Biochemistry 47:11086–96.

Bürkle A. (2005). Poly(ADP-ribose). The most elaborate metabolite of NAD+. FEBS J 272:4576–89.

Bürkle A, Virag L. (2013). Poly(ADP-ribose): PARadigms and PARadoxes. Mol Aspects Med 34:1046–65.

Canto C, Houtkooper RH, Pirinen E, et al. (2012). The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 15:838–47.

Cantoni GL. (1951). Methylation of nicotinamide with soluble enzyme system from rat liver. J Biol Chem 189:203–16.

Cerutti R, Pirinen E, Lamperti C, et al. (2014). NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 19:1042–9.

Chambers JE, Petrova K, Tomba G, et al. (2012). ADP ribosylation adapts an ER chaperone response to short-term fluctuations in unfolded protein load. J Cell Biol 198:371–85.

Chang HC, Guarente L. (2014). SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab 25:138–45.

Chapman K, Holmes M, Seckl J. (2013). 11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev 93:1139–206.

Chiarugi A, Dölle C, Felici R, et al. (2012). The NAD metabolome – a key determinant of cancer cell biology. Nat Rev Cancer 12:741–52.

Conforti L, Gilley J, Coleman MP. (2014). Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci 15:394–409.

Davis LC, Morgan AJ, Ruas M, et al. (2008). Ca(2+) signaling occurs via second messenger release from intraorganelle synthesis sites. Curr Biol 18:1612–18.

Dölle C, Niere M, Lohndal E, et al. (2010). Visualization of subcellular NAD pools and intra-organellar protein localization by poly-ADP-ribose formation. Cell Mol Life Sci 67:433–43.

Dölle C, Rack JG, Ziegler M. (2013a). NAD and ADP-ribose metabolism in mitochondria. FEBS J280:3530–41.

Dölle C, Skoge RH, Vanlinden MR, et al. (2013b). NAD biosynthesis in humans – enzymes, metabolites and therapeutic aspects. Curr Top Med Chem 13:2907–17.

Du J, Zhou Y, Su X, et al. (2011). Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334:806–9.

Durnin L, Dai Y, Aiba I, et al. (2012). Release, neuronal effects and removal of extracellular beta-nicotinamide adenine dinucleotide (beta-NAD(+)) in the rat brain. Eur J Neurosci 35:423–35.

Fabrizio G, Di Paola S, Stilla A, et al. (2015). ARTC1-mediated ADP-ribosylation of GRP78/BiP: a new player in endoplasmic-reticulum stress responses. Cell Mol Life Sci 72:1209–25.

Feijs KL, Verheugd P, Luscher B. (2013). Expanding functions of intracellular resident mono-ADP-ribosylation in cell physiology. FEBS J 280:3519–29.

Fliegert R, Gasser A, Guse AH. (2007). Regulation of calcium signalling by adenine-based second messengers. Biochem Soc Trans 35:109–14.

Formentini L, Macchiarulo A, Cipriani G, et al. (2009a). Poly(ADP-ribose) catabolism triggers AMP-dependent mitochondrial energy failure. J Biol Chem 284:17668–76.

Formentini L, Moroni F, Chiarugi A. (2009b). Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol 77:1612–20.

Franco L, Guida L, Bruzzone S, et al. (1998). The transmembrane glycoprotein CD38 is a catalytically active transporter responsible for generation and influx of the second messenger cyclic ADP-ribose across membranes. FASEB J 12:1507–20.

Frick DN, Bessman MJ. (1995). Cloning, purification, and properties of a novel NADH pyrophosphatase. Evidence for a nucleotide pyrophosphatase catalytic domain in MutT-like enzymes. J Biol Chem 270: 1529–34.

Fruscione F, Scarfi S, Ferraris C, et al. (2011). Regulation of human mesenchymal stem cell functions by an autocrine loop involving NAD + release and P2Y11-mediated signaling. Stem Cells Dev 20: 1183–98.

Fukuhara A, Matsuda M, Nishizawa M, et al. (2005). Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426–30.

Galione A. (2014). A primer of NAADP-mediated Ca^{2+} signalling: from sea urchin eggs to mammalian cells. Cell Calcium. [Epub ahead of print]. doi: 10.1016/j.ceca.2014.09.010.

Garavaglia S, Bruzzone S, Cassani C, et al. (2012). The high-resolution crystal structure of periplasmic Haemophilus influenzae NAD nucleotidase reveals a novel enzymatic function of human CD73 related to NAD metabolism. Biochem J 441:131–41.

Garten A, Petzold S, Korner A, et al. (2009). Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 20:130–8.

Gasser A, Glassmeier G, Fliegert R, et al. (2006). Activation of T cell calcium influx by the second messenger ADP-ribose. J Biol Chem 281:2489–96.

Gong B, Pan Y, Vempati P, et al. (2013). Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging 34:1581–8.

Gopal E, Miyauchi S, Martin PM, et al. (2007). Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract. Pharm Res 24:575–84.

Grimaldi G, Corda D, Catara G. (2015). From toxins to mammalian enzymes: the diversity of mono-ADP-ribosylation. Front Biosci (Landmark Ed) 20:389–404.

Grossman L, Kaplan NO. (1958). Nicotinamide riboside phosphorylase from human erythrocytes. II. Nicotinamide sensitivity. J Biol Chem 231:727–40.

Grozio A, Sociali G, Sturla L, et al. (2013). CD73 protein as a source of extracellular precursors for sustained NAD + biosynthesis in FK866-treated tumor cells. J Biol Chem 288:25938–49.

Grubisha O, Rafty LA, Takanishi CL, et al. (2006). Metabolite of SIR2 reaction modulates TRPM2 ion channel. J Biol Chem 281:14057–65.

Guillemin GJ. (2012). Quinolinic acid, the inescapable neurotoxin. FEBS J 279:1356–65.

Guse AH. (2014). Calcium mobilizing second messengers derived from NAD. Biochim Biophys Acta. [Epub ahead of print]. doi: 10.1016/j.bbapap.2014.12.015.

Haigis MC, Mostoslavsky R, Haigis KM, et al. (2006). SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 126:941–54.

Haigis MC, Sinclair DA. (2010). Mammalian sirtuins: biological insights and disease relevance. Annu Re Pathol 5:253–95.

Hassa PO, Hottiger MO. (2008). The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci-Landmrk 13:3046–82.

Hottiger MO, Hassa PO, Luscher B, et al. (2010). Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci 35:208–19.

Houtkooper RH, Canto C, Wanders RJ, et al. (2010). The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 31:194–223.

Houtkooper RH, Pirinen E, Auwerx J. (2012). Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 13:225–38.

Hunsucker SA, Mitchell BS, Spychala J. (2005). The 5′-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 107: 1–30.

Imai S, Armstrong CM, Kaeberlein M, et al. (2000). Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403:795–800.

Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate OBV, and Choline. (1998). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. In IOM SCSEDRI, ed. Washington (DC): National Academy Press, 123–49.

Ipata PL, Balestri F. (2013). The functional logic of cytosolic 5′-nucleotidases. Curr Med Chem 20:4205–16.

Itoh R, Saint-Marc C, Chaignepain S, et al. (2003). The yeast ISN1 (YOR155c) gene encodes a new type of IMP-specific 5′-nucleotidase. BMC Biochem 4:4.

Iwahara T, Bonasio R, Narendra V, et al. (2012). SIRT3 functions in the nucleus in the control of stress-related gene expression. Mol Cell Biol 32:5022–34.

Jackson MD, Denu JM. (2002). Structural identification of 2′- and 3′-O-acetyl-ADP-ribose as novel metabolites derived from the Sir2 family of beta -NAD+-dependent histone/protein deacetylases. J Biol Chem 277:18535–44.

Jankevicius G, Hassler M, Golia B, et al. (2013). A family of macrodomain proteins reverses cellular mono-ADP-ribosylation. Nat Struct Mol Biol 20:508–14.

Jia G, Fu Y, Zhao X, et al. (2011). N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol 7: 885–7.

Kanai Y, Segawa H, Miyamoto K, et al. (1998). Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273:23629–32.

Kasamatsu A, Nakao M, Smith BC, et al. (2011). Hydrolysis of O-acetyl-ADP-ribose isomers by ADP-ribosylhydrolase 3. J Biol Chem 286: 21110–17.

Khan NA, Auranen M, Paetau I, et al. (2014). Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol Med 6:721–31.

Kim UH, Kim MK, Kim JS, et al. (1993). Purification and character-ization of NAD glycohydrolase from rabbit erythrocytes. Arch Biochem Biophys 305:147–52.

Koch-Nolte F, Kernstock S, Mueller-Dieckmann C, et al. (2008). Mammalian ADP-ribosyltransferases and ADP-ribosylhydrolases. Front Biosci 13:6716–29.

Kraus D, Yang Q, Kong D, et al. (2014). Nicotinamide N-methyl-transferase knockdown protects against diet-induced obesity. Nature 508:258–62.

Landry J, Sutton A, Tafrov ST, et al. (2000). The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci USA 97:5807–11.

Lee HC, Aarhus R. (1995). A derivative of NADP mobilizes calcium stores insensitive to inositol trisphosphate and cyclic ADP-ribose. J Biol Chem 270:2152–7.

Lee HC. (2012). Cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) as messengers for calcium mobil-ization. J Biol Chem 287:31633–40.

Lee HC, Walseth TF, Bratt GT, et al. (1989). Structural determination of a cyclic metabolite of NAD+ with intracellular Ca2+-mobilizing activity. J Biol Chem 264:1608–15.

Lee YH, Nair S, Rousseau E, et al. (2005). Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes. Diabetologia 48:1776–83.

Leno GH, Ledford BE. (1989). ADP-ribosylation of the 78-kDa glucose-regulated protein during nutritional stress. Eur J Biochem 186:205–11.

Lin S, Gasmi L, Xie Y, et al. (2002). Cloning, expression and characterisation of a human Nudix hydrolase specific for adenosine 5′-diphosphoribose (ADP-ribose). Biochim Biophys Acta 1594: 127–35.

Lin W, Ame JC, Aboul-Ela N, et al. (1997). Isolation and characteriza-tion of the cDNA encoding bovine poly(ADP-ribose) glycohydrolase. J Biol Chem 272:11895–901.

Lu SC. (2000). S-Adenosylmethionine. IntJ Biochem Cell Biol 32: 391–5.

Lu SP, Lin SJ. (2011). Phosphate-responsive signaling pathway is a novel component of NAD+ metabolism in Saccharomyces cerevisiae. J Biol Chem 286:14271–81.

Luo M. (2012). Current chemical biology approaches to interrogate protein methyltransferases. ACS Chem Biol 7:443–63.

Ma B, Pan SJ, Zupancic ML, et al. (2007). Assimilation of NAD(+) precursors in Candida glabrata. Mol Microbiol 66:14–25.

Magni G, Amici A, Emanuelli M, et al. (2004). Enzymology of NAD + homeostasis in man. Cell Mol Life Sci 61:19–34.

Magni G, Orsomando G, Raffelli N, et al. (2008). Enzymology of mammalian NAD metabolism in health and disease. Front Biosci-Landmrk 13:6135–54.

Magni G, Di Stefano M, Orsomando G, et al. (2009). NAD(P) biosynthesis enzymes as potential targets for selective drug design. Curr Med Chem 16:1372–90.

Malavasi F, Deaglio S, Funaro A, et al. (2008). Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 88:841–86.

Mao Z, Hine C, Tian X, et al. (2011). SIRT6 promotes DNA repair under stress by activating PARP1. Science 332:1443–6.

Martinez-Redondo P, Vaquero A. (2013). The diversity of histone versus nonhistone sirtuin substrates. Genes Cancer 4:148–63.

Mashimo M, Kato J, Moss J. (2013). ADP-ribosyl-acceptor hydrolase 3 regulates poly (ADP-ribose) degradation and cell death during oxidative stress. Proc Natl Acad Sci USA 110:18964–9.

McLennan AG. (2006). The Nudix hydrolase superfamily. Cell Mol Life Sci 63:123–43.

Michishita E, Park JY, Burneskis JM, et al. (2005). Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16:4623–35.

Michishita E, McCord RA, Berber E, et al. (2008). SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 452: 492–6.

Moreschi I, Bruzzone S, Nicholas RA, et al. (2006). Extracellular NAD + is an agonist of the human P2Y11 purinergic receptor in human granulocytes. J Biol Chem 281:31419–29.

Moriwaki Y, Yamamoto T, Higashino K. (1999). Enzymes involved in purine metabolism – a review of histochemical localization and functional implications. Histol Histopathol 14:1321–40.

Moss J, Stanley SJ, Nightingale MS, et al. (1992). Molecular and immunological characterization of ADP-ribosylarginine hydrolases. J Biol Chem 267:10481–8.

Mueller-Dieckmann C, Kernstock S, Lisurek M, et al. (2006). The structure of human ADP-ribosylhydrolase 3 (ARH3) provides insights into the reversibility of protein ADP-ribosylation. Proc Natl Acad Sci USA 103:15026–31.

Mutafova-Yambolieva VN, Hwang SJ, Hao X, et al. (2007). Beta-nicotinamide adenine dinucleotide is an inhibitory neurotransmitter in visceral smooth muscle. Proc Natl Acad Sci USA 104:16359–64.

Nakanishi T, Sekimizu K. (2002). SDT1/SSM1, a multicopy suppressor of S-II null mutant, encodes a novel pyrimidine 5′-nucleotidase. J Biol Chem 277:22103–6.

Niere M, Mashimo M, Agledal L, et al. (2012). ADP-ribosylhydrolase 3 (ARH3), not poly(ADP-ribose) glycohydrolase (PARG) isoforms, is responsible for degradation of mitochondrial matrix-associated poly(ADP-ribose). J Biol Chem 287:16088–102.

Nikiforov A, Dölle C, Niere M, et al. (2011). Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J Biol Chem 286:21767–78.

O'Reilly T, Niven DF. (2003). Levels of nicotinamide adenine dinucleotide in extracellular body fluids of pigs may be growth-limiting for Actinobacillus pleuropneumoniae and Haemophilus parasuis. Can J Vet Res 67:229–31.

Oka S, Kato J, Moss J. (2006). Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J Biol Chem 281:705–13.

Ono T, Kasamatsu A, Oka S, et al. (2006). The 39-kDa poly(ADP-ribose) glycohydrolase ARH3 hydrolyzes O-acetyl-ADP-ribose, a product of the Sir2 family of acetyl-histone deacetylases. Proc Natl Acad Sci USA 103:16687–91.

Palmieri F, Rieder B, Ventrella A, et al. (2009). Molecular identification and functional characterization of Arabidopsis thaliana mitochondrial and chloroplastic NAD + carrier proteins. J Biol Chem 284:31249–59.

Palmieri F. (2013). The mitochondrial transporter family SLC25: identification, properties and physiopathology. Mol Aspects Med 34: 465–84.

Patel S, Marchant JS, Brailoiu E. (2010). Two-pore channels: regulation by NAADP and customized roles in triggering calcium signals. Cell Calcium 47:480–90.

Perraud AL, Fleig A, Dunn CA, et al. (2001). ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology. Nature 411:595–9.

Perraud AL, Shen B, Dunn CA, et al. (2003). NUDT9, a member of the Nudix hydrolase family, is an evolutionarily conserved mitochondrial ADP-ribose pyrophosphatase. J Biol Chem 278:1794–801.

Piccirella S, Czegle I, Lizak B, et al. (2006). Uncoupled redox systems in the lumen of the endoplasmic reticulum. Pyridine nucleotides stay reduced in an oxidative environment. J Biol Chem 281:4671–7.

Pillai SM, Meredith D. (2011). SLC36A4 (hPAT4) is a high affinity amino acid transporter when expressed in Xenopus laevis oocytes. J Biol Chem 286:2455–60.

Pittelli M, Felici R, Pitozzi V, et al. (2011). Pharmacological effects of exogenous NAD on mitochondrial bioenergetics, DNA repair, and apoptosis. Mol Pharmacol 80:1136–46.

Pittelli M, Formentini L, Faraco G, et al. (2010). Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J Biol Chem 285:34106–14.

Podesta M, Benvenuto F, Pitto A, et al. (2005). Concentrative uptake of cyclic ADP-ribose generated by BST-1 + stroma stimulates proliferation of human hematopoietic progenitors. J Biol Chem 280:5343–9.

Preiss J, Handler P. (1958a). Biosynthesis of diphosphopyridine nucleotide. II. Enzymatic aspects. J Biol Chem 233:493–500.

Preiss J, Handler P. (1958b). Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates. J Biol Chem 233: 488–92.

Preugschat F, Carter LH, Boros EE, et al. (2014). A pre-steady state and steady state kinetic analysis of the N-ribosyl hydrolase activity of hCD157. Arch Biochem Biophys 564:156–63.

Revollo JR, Korner A, Mills KF, et al. (2007). Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6:363–75.

Roessler M, Rollinger W, Palme S, et al. (2005). Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res 11:6550–7.

Rokka A, Antonenkov VD, Soininen R, et al. (2009). Pxmp2 is a channel-forming protein in Mammalian peroxisomal membrane. PLoS One 4:e5090.

Rosenthal F, Feijs KL, Frugier E, et al. (2013). Macrodomain-containing proteins are new mono-ADP-ribosylhydrolases. Nat Struct Mol Biol 20:502–7.

Rowen JW, Kornberg A. (1951). The phosphorolysis of nicotinamide riboside. J Biol Chem 193:497–507.

Samal B, Sun Y, Stearns G, et al. (1994). Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14:1431–7.

Sartini D, Morganti S, Guidi E, et al. (2013). Nicotinamide N-methyltransferase in non-small cell lung cancer: promising results for targeted anti-cancer therapy. Cell Biochem Biophys 67:865–73.

Scher MB, Vaquero A, Reinberg D. (2007). SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev 21:920–8.

Schroder M, Kaufman RJ. (2005). The mammalian unfolded protein response. Annu Rev Biochem 74:739–89.

Seman M, Adriouch S, Haag F, et al. (2004). Ecto-ADP-ribosyltransferases (ARTs): emerging actors in cell communication and signaling. Curr Med Chem 11:857–72.

Seman M, Adriouch S, Scheuplein F, et al. (2003). NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity 19:571–82.

Senesi S, Csala M, Marcolongo P, et al. (2010). Hexose-6-phosphate dehydrogenase in the endoplasmic reticulum. Biol Chem 391:1–8.

Sharifi R, Morra R, Appel CD, et al. (2013). Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease. EMBO J 32:1225–37.

Shimizu M, Masuo S, Fujita T, et al. (2012). Hydrolase controls cellular NAD, sirtuin, and secondary metabolites. Mol Cell Biol 32: 3743–55.

Shimizu M, Takaya N. (2013). Nudix hydrolase controls nucleotides and glycolytic mechanisms in hypoxic Aspergillus nidulans. Biosci Biotechnol Biochem 77:1888–93.

Slade D, Dunstan MS, Barkauskaite E, et al. (2011). The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase. Nature 477:616–20.

Smith JS, Brachmann CB, Celic I, et al. (2000). A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci USA 97:6658–63.

Smyth LM, Bobalova J, Mendoza MG, et al. (2004). Release of beta-nicotinamide adenine dinucleotide upon stimulation of postganglionic nerve terminals in blood vessels and urinary bladder. J Biol Chem 279:48893–903.

Song EK, Rah SY, Lee YR, et al. (2011). Connexin-43 hemichannels mediate cyclic ADP-ribose generation and its Ca2+-mobilizing activity by NAD+/cyclic ADP-ribose transport. J Biol Chem 286: 44480–90.

Stein LR, Imai S. (2012). The dynamic regulation of NAD metabolism in mitochondria. Trends Endocrinol Metab 23:420–8.

Sumoza-Toledo A, Penner R. (2011). TRPM2: a multifunctional ion channel for calcium signalling. J Physiol 589:1515–25.

Takasawa S, Okamoto H. (2002). Pancreatic beta-cell death, regeneration and insulin secretion: roles of poly(ADP-ribose) polymerase and cyclic ADP-ribose. Int J Exp Diabetes Res 3:79–96.

Tang SW, Yang TC, Lin WC, et al. (2011). Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis 32:138–45.

Tanner KG, Landry J, Sternglanz R, et al. (2000). Silent information regulator 2 family of NAD-dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc Natl Acad Sci USA 97:14178–82.

Tempel W, Rabeh WM, Bogan KL, et al. (2007). Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol 5:e263.

Todisco S, Agrimi G, Castegna A, et al. (2006). Identification of the mitochondrial NAD + transporter in Saccharomyces cerevisiae. J Biol Chem 281:1524–31.

Trammell SA, Brenner C. (2013). Targeted, LCMS-based metabolomics for quantitative measurement of NAD(+) metabolites. Comput Struct Biotechnol J 4:e201301012.

Ulanovskaya OA, Zuhl AM, Cravatt BF. (2013). NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol 9:300–6.

Ulrey CL, Liu L, Andrews LG, et al. (2005). The impact of metabolism on DNA methylation. Hum Mol Genet 14:R139–47.

Verderio C, Bruzzone S, Zocchi E, et al. (2001). Evidence of a role for cyclic ADP-ribose in calcium signalling and neurotransmitter release in cultured astrocytes. J Neurochem 78:646–57.

Wanders RJ, Waterham HR. (2006). Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem 75:295–332.

Watson M, Roulston A, Belec L, et al. (2009). The small molecule GMX1778 is a potent inhibitor of NAD + biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol 29:5872–88.

Wielgus-Kutrowska B, Kulikowska E, Wierzchowski J, et al. (1997). Nicotinamide riboside, an unusual, non-typical, substrate of purified purine-nucleoside phosphorylases. Eur J Biochem 243:408–14.

Williams AC, Cartwright LS, Ramsden DB. (2005). Parkinson's disease: the first common neurological disease due to auto-intoxication? QJM 98:215–26.

Wu Y, Siadaty MS, Berens ME, et al. (2008). Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene 27:6679–89.

Yaguchi H, Togawa K, Moritani M, et al. (2005). Identification of candidate genes in the type 2 diabetes modifier locus using expression QTL. Genomics 85:591–9.

Yamamoto T, Byun J, Zhai P, et al. (2014). Nicotinamide mononucleotide, an intermediate of NAD + synthesis, protects the heart from ischemia and reperfusion. PLoS One 9:e98972.

Yang H, Yang T, Baur JA, et al. (2007). Nutrient-sensitive mitochondrial NAD + levels dictate cell survival. Cell 130:1095–107.

Yoshino J, Mills KF, Yoon MJ, *et al*. (2011). Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 14: 528–36.

Zhao YJ, Lam CM, Lee HC. (2012). The membrane-bound enzyme CD38 exists in two opposing orientations. Sci Signal 5:ra67.

Zhao YJ, Zhu WJ, Wang XW, *et al*. (2014). Determinants of the membrane orientation of a calcium signaling enzyme CD38. Biochim Biophys Acta. [Epub ahead of print]. doi: 10.1016/j.bbamcr.2014.10.028.

Zocchi E, Usai C, Guida L, *et al*. (1999). Ligand-induced internalization of CD38 results in intracellular Ca^{2+} mobilization: role of NAD^+ transport across cell membranes. FASEB J 13:273–83.